Financial News
All News about Fate Therapeutics, Inc. - Common Stock
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Analyst Ratings for Fate Therapeutics
September 07, 2023
Via Benzinga
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
The Latest Analyst Ratings for Fate Therapeutics
August 16, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_10164.png?width=1200&height=800&fit=crop)
Where Fate Therapeutics Stands With Analysts
May 05, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Fate Therapeutics: Q1 Earnings Insights
May 03, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Fate Therapeutics Earnings Preview
May 02, 2023
Via Benzinga
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
15 Analysts Have This to Say About Fate Therapeutics
March 27, 2023
Via Benzinga
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
![](https://mms.businesswire.com/media/20230630496489/en/1510725/22/Latest_KSF_SEC.jpg)
![](https://mms.businesswire.com/media/20230621334242/en/538768/22/BES_Mark.jpg)
![](https://g.foolcdn.com/editorial/images/736660/biotech.jpg)
![](https://mms.businesswire.com/media/20230608005730/en/538768/22/BES_Mark.jpg)
![](https://mms.businesswire.com/media/20230605005653/en/1510725/22/Latest_KSF_SEC.jpg)
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/04/24/image22.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg)
![](https://mms.businesswire.com/media/20230322005579/en/1164042/5/July_30%2C_2021_-_ROSEN_LOGO.jpg)
![](https://mms.businesswire.com/media/20230321005954/en/538768/22/BES_Mark.jpg)
![](https://mms.businesswire.com/media/20230321005419/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
Topics
Lawsuit
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
Topics
Lawsuit
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.